aminolevulinic acid HCl
Phase 1Small molecule
aminolevulinic acid HCl is one of 19 small molecule programs targeting Actinic Keratoses. It is currently in Phase 1.
2
Indications
3
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
21 competitors in Basal Cell Carcinoma
#DrugCompanyPhaseTrials
1Erivedge
RocheApproved
Aldara
BBausch Health Americas, Inc.
Approved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Adriamycin
PfizerApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Retin-a
VValeant Pharmaceuticals
Approved
Adrucil
EElorac, Inc.
Approved
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Libtayo
RegeneronPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Basal Cell Carcinoma1 trial
Acne1 trial
Actinic Keratoses1 trial
Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States
Withdrawn·—·N/A·NCT02867722
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for aminolevulinic acid HCl. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDUSA Pharmaceuticals, Inc.